Zydus Cadila gets USFDA nod for drug trials to treat chemotherapy-induced anemia

By: |
Updated: Jul 23, 2020 12:07 PM

Desidustat is a novel drug which is also currently undergoing phase-III trials for treating anemia in chronic kidney disease patients and phase-II studies for management of COVID-19 patients.

Zydus Cadila, USFDA, anemia, chemotherapy, COVID-19 patients, Desidustat, kidney disease,latest news on zydus cadilaIn a regulatory filing, Zydus Cadila said it has received approval from the US Food and Drug Administration (USFDA) to initiate clinical trials of Desidustat in CIA. (Representational image)

Drug firm Zydus Cadila on Thursday said it has received approval from the US health regulator to initiate clinical trials for its drug ‘Desidustat’ in treatment of chemotherapy-induced anemia (CIA). Desidustat is a novel drug which is also currently undergoing phase-III trials for treating anemia in chronic kidney disease patients and phase-II studies for management of COVID-19 patients.

In a regulatory filing, Zydus Cadila said it has received approval from the US Food and Drug Administration (USFDA) to initiate clinical trials of Desidustat in CIA. Zydus Cadila Chairman Pankaj R Patel said CIA is a serious unmet medical need and there is a need for novel therapies to address this condition.

”Desidustat has been specifically designed to improve haemoglobin, reduce hepcidin and thereby treat anemia,” he added. Shares of Cadila Healthcare, the listed entity of the group, were trading at Rs 369.95 apiece on BSE, 0.91 per cent higher against their previous close.

Get live Stock Prices from BSE, NSE, US Market and latest NAV, portfolio of Mutual Funds, calculate your tax by Income Tax Calculator, know market’s Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.

Financial Express is now on Telegram. Click here to join our channel and stay updated with the latest Biz news and updates.

Next Stories
1Serum Institute says vaccine viable even at 60% to 70% efficacy
2After dip, labs look at increase in demand for RT-PCR tests again
3Night curfew to be clamped in Delhi due to rising Covid-19 cases? Here’s what AAP govt told High Court